featured
Long-Term Overall Survival Benefits With Tebentafusp in Patients With Metastatic Uveal Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
N. Engl. J. Med 2023 Oct 21;[EPub Ahead of Print], JC Hassel, S Piperno-Neumann, P Rutkowski, JF Baurain, M Schlaak, MO Butler, RJ Sullivan, R Dummer, JM Kirkwood, M Orloff, JJ Sacco, S Ochsenreither, AM Joshua, L Gastaud, B Curti, JM Piulats, AKS Salama, AN Shoushtari, L Demidov, M Milhem, B Chmielowski, KB Kim, RD Carvajal, O Hamid, L Collins, K Ranade, C Holland, C Pfeiffer, P NathanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.